Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Eli Lilly and Company (NYSE:LLY) and Verve Therapeutics, Inc. (NASDAQ:VERV) today announced that the tender offer to purchase a...
BMO Capital analyst Kostas Biliouris downgrades Verve Therapeutics (NASDAQ:VERV) from Outperform to Market Perform and lower...
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...
HC Wainwright & Co. analyst Mitchell Kapoor downgrades Verve Therapeutics (NASDAQ:VERV) from Buy to Neutral and maintain...
LifeSci Capital analyst Cory Jubinville downgrades Verve Therapeutics (NASDAQ:VERV) from Outperform to Market Perform and an...
Jefferies analyst Roger Song downgrades Verve Therapeutics (NASDAQ:VERV) from Buy to Hold and lowers the price target from $...
